Cartesian Therapeutics (RNAC) and The Competition Head-To-Head Analysis

Cartesian Therapeutics (NASDAQ:RNAC) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Cartesian Therapeutics to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Cartesian Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-510.72%	N/A	-6.03%
Cartesian Therapeutics Competitors	-3,590.11%	-276.96%	-39.10%

Insider & Institutional Ownership

86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Cartesian Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics’ rivals have a beta of 3.79, indicating that their average stock price is 279% more volatile than the S&P 500.

Valuation & Earnings

This table compares Cartesian Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cartesian Therapeutics	$47.94 million	-$219.71 million	-0.37
Cartesian Therapeutics Competitors	$9.58 billion	$147.39 million	-5.43

Cartesian Therapeutics’ rivals have higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings for Cartesian Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	2	8	0	2.80
Cartesian Therapeutics Competitors	7807	21249	48919	1239	2.55

Cartesian Therapeutics presently has a consensus target price of $42.86, suggesting a potential upside of 116.56%. As a group, “Pharmaceutical preparations” companies have a potential upside of 186.13%. Given Cartesian Therapeutics’ rivals higher probable upside, analysts plainly believe Cartesian Therapeutics has less favorable growth aspects than its rivals.

Summary

Cartesian Therapeutics beats its rivals on 8 of the 13 factors compared.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.